Eur J Pediatr Surg 2014; 24(06): 461-466
DOI: 10.1055/s-0034-1396420
Review Article
Georg Thieme Verlag KG Stuttgart · New York

Advances in Fibrolamellar Hepatocellular Carcinoma: A Review

Irene Isabel P. Lim
1   Department of Surgery, Pediatric Surgical Service, Memorial Sloan Kettering Cancer Center, New York, New York, United States
,
Benjamin A. Farber
1   Department of Surgery, Pediatric Surgical Service, Memorial Sloan Kettering Cancer Center, New York, New York, United States
,
Michael P. LaQuaglia
1   Department of Surgery, Pediatric Surgical Service, Memorial Sloan Kettering Cancer Center, New York, New York, United States
› Author Affiliations
Further Information

Publication History

20 October 2014

24 October 2014

Publication Date:
08 December 2014 (online)

Abstract

Fibrolamellar hepatocellular carcinoma is a rare primary liver tumor that often arises in the absence of cirrhosis or viral hepatitis. Compared with hepatocellular carcinoma, patients are typically younger with less comorbidities. Diagnosis is often multimodal and requires a high level of suspicion, as traditional liver pathology markers, such as serum α fetoprotein and transaminases, are often normal. Overall, patients respond well to surgical resection but recurrences are frequent, and alternative therapies, such as chemotherapy and radiation, are not well studied. Currently, there are no established chemotherapy regimens; there are only limited case reports of select agents, such as 5-fluorouracil with interferon-α and gemcitabine with oxaliplatin, used with varying degrees of success. Because little is known about this rare tumor, the development of serum markers and alternative therapies continues to be a challenge. A major advancement in the understanding of this rare disease is the discovery of a functional chimeric transcript incorporating DNAJB1 and PRKACA. This finding may finally provide the basis for specific diagnostic markers and chemotherapies that patients with this disease have long needed. Here, we present advances in the surgical treatment of fibrolamellar hepatocellular carcinoma, as well as recent data on its tumor biology and pathogenesis.

 
  • References

  • 1 Edmondson HA. Differential diagnosis of tumors and tumor-like lesions of liver in infancy and childhood. AMA J Dis Child 1956; 91 (2) 168-186
  • 2 Fonseca GM, Varella AD, Coelho FF, Abe ES, Dumarco RB, Herman P. Downstaging and resection after neoadjuvant therapy for fibrolamellar hepatocellular carcinoma. World J Gastrointest Surg 2014; 6 (6) 107-111
  • 3 Okur A, Eser EP, Yilmaz G , et al. Successful multimodal treatment for aggressive metastatic and recurrent fibrolamellar hepatocellular carcinoma in a child. J Pediatr Hematol Oncol 2014; 36 (5) e328-e332
  • 4 Maniaci V, Davidson BR, Rolles K , et al. Fibrolamellar hepatocellular carcinoma: prolonged survival with multimodality therapy. Eur J Surg Oncol 2009; 35 (6) 617-621
  • 5 Torbenson M. Fibrolamellar carcinoma: 2012 update. Scientifica (Cairo) 2012; 2012: 743790
  • 6 Paradis V. Histopathology of hepatocellular carcinoma. Recent Results Cancer Res 2013; 190: 21-32
  • 7 Ganeshan D, Szklaruk J, Kundra V, Kaseb A, Rashid A, Elsayes KM. Imaging features of fibrolamellar hepatocellular carcinoma. AJR Am J Roentgenol 2014; 202 (3) 544-552
  • 8 Eggert T, McGlynn KA, Duffy A, Manns MP, Greten TF, Altekruse SF. Fibrolamellar hepatocellular carcinoma in the USA, 2000–2010: A detailed report on frequency, treatment and outcome based on the Surveillance, Epidemiology, and End Results database. United European Gastroenterol J 2013; 1 (5) 351-357
  • 9 Kaseb AO, Shama M, Sahin IH , et al. Prognostic indicators and treatment outcome in 94 cases of fibrolamellar hepatocellular carcinoma. Oncology 2013; 85 (4) 197-203
  • 10 Eggert T, McGlynn KA, Duffy A, Manns MP, Greten TF, Altekruse SF. Epidemiology of fibrolamellar hepatocellular carcinoma in the USA, 2000–10. Gut 2013; 62 (11) 1667-1668
  • 11 Ward SC, Huang J, Tickoo SK, Thung SN, Ladanyi M, Klimstra DS. Fibrolamellar carcinoma of the liver exhibits immunohistochemical evidence of both hepatocyte and bile duct differentiation. Mod Pathol 2010; 23 (9) 1180-1190
  • 12 Zen Y, Vara R, Portmann B, Hadzic N. Childhood hepatocellular carcinoma: a clinicopathological study of 12 cases with special reference to EpCAM. Histopathology 2014; 64 (5) 671-682
  • 13 Malouf GG, Job S, Paradis V , et al. Transcriptional profiling of pure fibrolamellar hepatocellular carcinoma reveals an endocrine signature. Hepatology 2014; 59 (6) 2228-2237
  • 14 Muramori K, Taguchi S, Taguchi T , et al. High aromatase activity and overexpression of epidermal growth factor receptor in fibrolamellar hepatocellular carcinoma in a child. J Pediatr Hematol Oncol 2011; 33 (5) e195-e197
  • 15 Sulaiman RA, Geberhiwot T. Fibrolamellar hepatocellular carcinoma mimicking ornithine transcarbamylase deficiency. JIMD Rep 2014; ; [Epub ahead of print]
  • 16 Riehle KJ, Yeh MM, Yu JJ , et al. mTORC1 and FGFR1 signaling in fibrolamellar hepatocellular carcinoma. Mod Pathol 2014; ; [Epub ahead of print]
  • 17 Honeyman JN, Simon EP, Robine N , et al. Detection of a recurrent DNAJB1-PRKACA chimeric transcript in fibrolamellar hepatocellular carcinoma. Science 2014; 343 (6174) 1010-1014
  • 18 Xu L, Hazard FK, Zmoos AF , et al. Genomic analysis of fibrolamellar hepatocellular carcinoma. Hum Mol Genet 2014; ; [Epub ahead of print]
  • 19 Ward SC, Waxman S. Fibrolamellar carcinoma: a review with focus on genetics and comparison to other malignant primary liver tumors. Semin Liver Dis 2011; 31 (1) 61-70
  • 20 Ang CS, Kelley RK, Choti MA , et al. Clinicopathologic characteristics and survival outcomes of patients with fibrolamellar carcinoma: data from the fibrolamellar carcinoma consortium. Gastrointest Cancer Res 2013; 6 (1) 3-9
  • 21 Kanai T, Takabayashi T, Kawano Y, Kuramochi S, Miyazawa N. A case of postoperative recurrence of fibrolamellar hepatocellular carcinoma with increased vitamin B12 binding capacity in a young Japanese female. Jpn J Clin Oncol 2004; 34 (6) 346-351
  • 22 Groeschl RT, Miura JT, Wong RK , et al. Multi-institutional analysis of recurrence and survival after hepatectomy for fibrolamellar carcinoma. J Surg Oncol 2014; 110 (4) 412-415
  • 23 Patonai A, Erdélyi-Belle B, Korompay A , et al. Molecular characteristics of fibrolamellar hepatocellular carcinoma. Pathol Oncol Res 2013; 19 (1) 63-70
  • 24 Liu S, Wah Chan K, Tong J, Wang Y, Wang B, Qiao L. PET-CT scan is a valuable modality in the diagnosis of fibrolamellar hepatocellular carcinoma: a case report and a summary of recent literature. QJM 2011; 104 (6) 477-483
  • 25 Sun L, Wu H, Guan YS. Positron emission tomography/computer tomography: challenge to conventional imaging modalities in evaluating primary and metastatic liver malignancies. World J Gastroenterol 2007; 13 (20) 2775-2783
  • 26 Do RK, McErlean A, Ang CS, DeMatteo RP, Abou-Alfa GK. CT and MRI of primary and metastatic fibrolamellar carcinoma: a case series of 37 patients. Br J Radiol 2014; 87 (1040) 20140024
  • 27 G Peacock J, A Call J, R Olivier K Radiotherapy for metastatic fibrolamellar hepatocellular carcinoma. Rare Tumors 2013; 5 (3) e28
  • 28 Trojan J, Schroeder O, Raedle J , et al. Fluorine-18 FDG positron emission tomography for imaging of hepatocellular carcinoma. Am J Gastroenterol 1999; 94 (11) 3314-3319
  • 29 von Falck C, Rodt T, Shin HO, Knapp WH, Galanski M. F-18 FDG PET imaging of fibrolamellar hepatocellular carcinoma. Clin Nucl Med 2008; 33 (9) 633-634
  • 30 Weeda VB, Murawski M, McCabe AJ , et al. Fibrolamellar variant of hepatocellular carcinoma does not have a better survival than conventional hepatocellular carcinoma—results and treatment recommendations from the Childhood Liver Tumour Strategy Group (SIOPEL) experience. Eur J Cancer 2013; 49 (12) 2698-2704
  • 31 Katzenstein HM, Krailo MD, Malogolowkin MH , et al. Fibrolamellar hepatocellular carcinoma in children and adolescents. Cancer 2003; 97 (8) 2006-2012
  • 32 Darcy DG, Malek M. M., Kobos, R., Klimstra, D.S., DeMattero, R., LaQuaglia, M.P. Prognostic factors in fibrolamellar hepatocellular carcinoma in young people. J Pediatr Surg 2014; ; In press DOI
  • 33 Mavros MN, Mayo SC, Hyder O, Pawlik TM. A systematic review: treatment and prognosis of patients with fibrolamellar hepatocellular carcinoma. J Am Coll Surg 2012; 215 (6) 820-830
  • 34 Minutolo V, Licciardello A, Arena M, Minutolo O, Lanteri R, Arena G. Surgical resection of ruptured fibrolamellar hepatocellular carcinoma. Case Rep Surg 2013; 2013: 679565
  • 35 Stipa F, Yoon SS, Liau KH , et al. Outcome of patients with fibrolamellar hepatocellular carcinoma. Cancer 2006; 106 (6) 1331-1338
  • 36 Wojcicki M, Lubikowski J, Post M, Chmurowicz T, Wiechowska-Kozlowska A, Krawczyk M. Aggressive surgical management of recurrent lymph node and pancreatic head metastases of resected fibrolamellar hepatocellular carcinoma: a case report. JOP 2012; 13 (5) 529-532
  • 37 Mayo SC, Mavros MN, Nathan H , et al. Treatment and prognosis of patients with fibrolamellar hepatocellular carcinoma: a national perspective. J Am Coll Surg 2014; 218 (2) 196-205
  • 38 McAteer JP, Goldin AB, Healey PJ, Gow KW. Hepatocellular carcinoma in children: epidemiology and the impact of regional lymphadenectomy on surgical outcomes. J Pediatr Surg 2013; 48 (11) 2194-2201
  • 39 Mazzaferro V, Regalia E, Doci R , et al. Liver transplantation for the treatment of small hepatocellular carcinomas in patients with cirrhosis. N Engl J Med 1996; 334 (11) 693-699
  • 40 Grossman EJ, Millis JM. Liver transplantation for non-hepatocellular carcinoma malignancy: Indications, limitations, and analysis of the current literature. Liver Transpl 2010; 16 (8) 930-942
  • 41 Hackl C, Schlitt HJ, Kirchner GI, Knoppke B, Loss M. Liver transplantation for malignancy: current treatment strategies and future perspectives. World J Gastroenterol 2014; 20 (18) 5331-5344
  • 42 Fakih M. A case of fibrolamellar cancer with a palliative response and minor radiographic regression with erlotinib and bevacizumab combination therapy. Am J Ther 2013; : doi: 10.1097/MJT.0b013e3182840fa6
  • 43 Gras P, Truant S, Boige V , et al. Prolonged complete response after GEMOX chemotherapy in a patient with advanced fibrolamellar hepatocellular carcinoma. Case Rep Oncol 2012; 5 (1) 169-172